Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination

International Journal of Biochemistry and Cell Biology

Volumn 53, Issue , 2014, Pages 46-50

  Hailemichael, Yared ^a   Overwijk, Willem W ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Immunotherapy; Inflammation; T cells; Trafficking

Indexed keywords

CANCER VACCINE; CELL ADHESION MOLECULE; FAS LIGAND; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 100; PEPTIDE VACCINE; MELANOCYTE PROTEIN PMEL 17; PEPTIDE FRAGMENT;

APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER LOCALIZATION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL MIGRATION; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; HOST CELL; HUMAN; IMMUNOSTIMULATION; NONHUMAN; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MELANOMA; PEPTIDE FRAGMENTS; TUMOR MICROENVIRONMENT;

EID: 84901255770     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2014.04.019     Document Type: Short Survey

References (39)

1. C.L. Ahonen, C.L. Doxsee, S.M. McGurran, T.R. Riter, W.F. Wade, and R.J. Barth et al. Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN J Exp Med 199 2004 775 784 (Pubitemid 38375197)
2. R. Arens, T. van Hall, S.H. van der Burg, F. Ossendorp, and C.J. Melief Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer Semin Immunol 25 2013 182 190
3. F. Balkwill Cancer and the chemokine network Nat Rev Cancer 4 2004 540 550 (Pubitemid 38868623)
4. D. Bedognetti, E. Wang, M.R. Sertoli, and F.M. Marincola Gene-expression profiling in vaccine therapy and immunotherapy for cancer Expert Rev Vaccines 9 2010 555 565
5. D. Bedognetti, T.L. Spivey, Y. Zhao, L. Uccellini, S. Tomei, and M.E. Dudley et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 Brit J Cancer 109 2013 2412 2423
6. M. Bellone, and A. Calcinotto Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Front Oncol 3 2013 231
7. M.S. Bijker, S.J. van den Eeden, K.L. Franken, C.J. Melief, S.H. van der Burg, and R. Offringa Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged DC-focused antigen presentation Eur J Immunol 38 2008 1033 1042
8. F. Bonhoure, and J. Gaucheron Montanide ISA 51 VG as adjuvant for human vaccines J Immunother 29 2006 647 648
9. R.J. Buckanovich, A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, and K. Balint et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy Nat Med 14 2008 28 36
10. A. Calcinotto, M. Grioni, E. Jachetti, F. Curnis, A. Mondino, and G. Parmiani et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy J Immunol 188 2012 2687 2694
11. F. Castellino, A.Y. Huang, G. Altan-Bonnet, S. Stoll, C. Scheinecker, and R.N. Germain Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction Nature 440 2006 890 895
12. L. Diehl, A.T. den Boer, S.P. Schoenberger, E.I. van der Voort, T.N. Schumacher, and C.J. Melief et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 1999 774 779 (Pubitemid 29318611)
13. C.G. Drake, E.J. Lipson, and J.R. Brahmer Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Nat Rev Clin Oncol 11 2014 24 37
14. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 2009 162 174
15. T.F. Gajewski, M. Fuertes, R. Spaapen, Y. Zheng, and J. Kline Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment Curr Opin Immunol 23 2011 286 292
16. T.F. Gajewski, S.R. Woo, Y. Zha, R. Spaapen, Y. Zheng, and L. Corrales et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment Curr Opin Immunol 25 2013 268 276
17. S. Gnjatic, and N. Bhardwaj Antigen depots: T cell traps? Nat Med 19 2013 397 398
18. Y. Hailemichael, and W. Overwijk Peptide-based cancer vaccines: the making and unmaking of a T cell graveyard OncoImmunology 2013
19. Y. Hailemichael, Z. Dai, N. Jaffarzad, Y. Ye, M.A. Medina, and X.F. Huang et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Nat Med 19 2013 465 472
20. H. Harlin, Y. Meng, A.C. Peterson, Y. Zha, M. Tretiakova, and C. Slingluff et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment Cancer Res 69 2009 3077 3085
21. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
22. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
23. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, and A.P. Vloon et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl J Med 361 2009 1838 1847
24. C.J. Melief Cancer immunotherapy by dendritic cells Immunity 29 2008 372 383
25. C.J. Melief, and S.H. van der Burg Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat Rev Cancer 8 2008 135 360
26. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489
27. C. Monteagudo, J.M. Martin, E. Jorda, and A. Llombart-Bosch CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors J Clin Pathol 60 2007 596 599 (Pubitemid 46975211)
28. G.T. Motz, and G. Coukos The parallel lives of angiogenesis and immunosuppression: cancer and other tales Nat Rev Immunol 11 2011 702 711
29. W. Peng, Y. Ye, B.A. Rabinovich, C. Liu, Y. Lou, and M. Zhang et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses Clin Cancer Res 16 2010 5458 5468
30. A.P. Rapoport, N.A. Aqui, E.A. Stadtmauer, D.T. Vogl, Y.Y. Xu, and M. Kalos et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells Clin Cancer Res 20 2014 1355 1365
31. R.L. Reinhardt, D.C. Bullard, C.T. Weaver, and M.K. Jenkins Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation J Exp Med 197 2003 751 762 (Pubitemid 36350870)
32. K. Rezvani, A.S. Yong, S. Mielke, B. Jafarpour, B.N. Savani, and R.Q. Le et al. Repeated PR1 and WT1 peptide vaccination in montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies Haematologica 96 2011 432 440
33. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat Med 10 2004 909 915 (Pubitemid 39273730)
34. S.A. Rosenberg, R.M. Sherry, K.E. Morton, W.J. Scharfman, J.C. Yang, and S.L. Topalian et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma J Immunol 175 2005 6169 6176 (Pubitemid 41508105)
35. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards, R.M. Conry, D.M. Miller, and J. Treisman et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
36. M.J. Smyth, G.P. Dunn, and R.D. Schreiber Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 2006 1 50 (Pubitemid 43765795)
37. D.E. Speiser, D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, and F. Lejeune et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide IFA, and CpG oligodeoxynucleotide 7909 J Clin Invest 115 2005 739 746 (Pubitemid 40322250)
38. S. Ugel, E. Peranzoni, G. Desantis, M. Chioda, S. Walter, and T. Weinschenk et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen Cell Rep 2 2012 628 639
39. S. Zwaveling, S.C. Ferreira Mota, J. Nouta, M. Johnson, G.B. Lipford, and R. Offringa et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J Immunol 169 2002 350 358 (Pubitemid 34686155)